SCHEMBL3155329

SCHEMBL3155329

CCOOC(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14190002 0.79 ALDH1A1 (0.31)
SCHEMBL2707847 0.78
SCHEMBL27882777 0.78
SCHEMBL919515 0.75 ALDH1A1 (0.47)
SCHEMBL1722804 0.74
SCHEMBL12922797 0.74
SCHEMBL117701 0.73
SCHEMBL1049538 0.73
SCHEMBL8747973 0.73 ALDH1A1 (0.45)
SCHEMBL919517 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897560-B1 COMPOSITION COMPRISING OXALAMIDE GELATORS AND VEGETABLE OIL RUDJER BOSKOVIC INST (HR) 2022-06-29 EP disclosed
US-20220023179-A1 COMPOSITION COMPRISING OXALAMIDE GELATORS AND VEGETABLE OIL RUDJER BOSKOVIC INSTITUTE (HR) 2022-01-27 US disclosed
US-20170073314-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-03-16 US disclosed
WO-2016023510-A1 MICROMOLECULE COMPOUND, METHOD OF SYNTHESIS AND APPLICATION THEREOF 嘉兴特科罗生物科技有限公司 2016-02-18 WO disclosed
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 US disclosed
US-8013006-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-09-06 US disclosed
CN-101273303-B Positive photosensitive resin composition ASAHI KASEI EMD CORP 2011-07-06 CN disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-7772271-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2010-08-10 US disclosed
US-7687208-B2 Positive photosensitive resin composition ASAHI KASEI EMD CORPORATION (JP) 2010-03-30 US disclosed
EP-1730120-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-12-13 EP disclosed
EP-1656353-A1 GABANERGIC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP disclosed
WO-2005090317-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2005-09-29 WO disclosed
US-20050215554-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2005-09-29 US disclosed
US-20050101614-A1 For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain ROCHE PALO ALTO LLC 2005-05-12 US disclosed
WO-2005016892-A1 GABANERGIC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-02-24 WO disclosed
EP-0530252-A4 AMINOALKYLCARBAMYL DERIVATIVES OF FORSKOLIN AS INTERMEDIATES FOR THE SYNTHESIS OF USEFUL FORSKOLIN DERIVATIVES US HEALTH (US) 1993-09-01 EP disclosed
EP-0530252-A1 AMINOALKYLCARBAMYL DERIVATIVES OF FORSKOLIN AS INTERMEDIATES FOR THE SYNTHESIS OF USEFUL FORSKOLIN DERIVATIVES THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) 1993-03-10 EP disclosed
EP-0127325-B1 DISPERSING AGENT IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1989-02-22 EP disclosed
EP-0127325-A2 Dispersing agent IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-12-05 EP disclosed